Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PARL | Q9H300 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12626117 | 0.85 | L3MBTL1 (0.50) | ALDH1A1L3MBTL1HCRTR1HCRTR2MEN1 | |
| SCHEMBL12621871 | 0.83 | GAA (0.59) | ALDH1A1L3MBTL1HCRTR1HCRTR2GAA | |
| SCHEMBL23159676 | 0.82 | L3MBTL1 (0.60) | ALDH1A1L3MBTL1HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL12626116 | 0.77 | HCRTR1 (0.42) | ALDH1A1L3MBTL1HCRTR1HCRTR2MEN1 | |
| SCHEMBL25493754 | 0.76 | L3MBTL1 (0.52) | ALDH1A1L3MBTL1HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL12622002 | 0.74 | POLB (0.64) | ALDH1A1L3MBTL1HCRTR1HCRTR2POLB | |
| SCHEMBL12656163 | 0.73 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1POLBTSHRSMN1; SMN2 | |
| SCHEMBL12661174 | 0.72 | HCRTR1 (0.56) | ALDH1A1L3MBTL1HCRTR1HCRTR2POLB | |
| SCHEMBL12622021 | 0.71 | HCRTR2 (0.69) | ALDH1A1L3MBTL1HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL12621863 | 0.70 | LMNA (0.62) | ALDH1A1L3MBTL1HCRTR1HCRTR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | ALDH1A1 4388/4885L3MBTL1 1789/4885HCRTR1 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.